2006
DOI: 10.1159/000096914
|View full text |Cite
|
Sign up to set email alerts
|

Scleromyxedema: Successful Treatment with Thalidomide in Two Patients

Abstract: Background: Scleromyxedema is an unusual skin disease characterized by mucinous infiltration of the skin. There is no satisfactory treatment for this disorder. Case Report: We report 2 cases of scleromyxedema, both associated with an IgG-λ paraprotein. Treatment with thalidomide was started and great improvement of the lesion was noted as shown by a quality of life questionnaire similar to those used in rheumatoid arthritis. TNF-α value was elevated in both cases during this treatment. Discussion: We hypothesi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
18
0

Year Published

2008
2008
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 27 publications
(21 citation statements)
references
References 12 publications
1
18
0
Order By: Relevance
“…Thalidomide has been approved for the treatment of multiple myeloma and erythema nodosum leprosum. Clinical trials are currently being conducted for its use in treating inflammatory diseases, various neoplastic diseases, complications of human immunodeficiency virus infection, chronic graft-versus-host disease and numerous dermatological conditions, among others [1,13,19,23,25,27,29,30,37,44].…”
Section: Introductionmentioning
confidence: 99%
“…Thalidomide has been approved for the treatment of multiple myeloma and erythema nodosum leprosum. Clinical trials are currently being conducted for its use in treating inflammatory diseases, various neoplastic diseases, complications of human immunodeficiency virus infection, chronic graft-versus-host disease and numerous dermatological conditions, among others [1,13,19,23,25,27,29,30,37,44].…”
Section: Introductionmentioning
confidence: 99%
“…Based on previous reports [10, 24, 25], we decided to treat our patient initially with thalidomide. After 3 months, we observed only a moderate improvement of the cutaneous lesions.…”
Section: Discussionmentioning
confidence: 99%
“…The rationale for using thalidomide as maintenance therapy in patients with scleromyxoedema was its recognized role in the treatment of refractory multiple myeloma, in which marked and durable responses counteracting plasr)ia cell dyscrasia were obtained with reduction of paraprotein levels (18)(19)(20)(21)(22). Moreover, thalidomide has been proposed to be an anti-fibrotic agent through its immuiioregulatory effect on pro-inflammatory and pro-fiblrotic cytokines in myelodysplastic syndrome with bone-marrow fibrosis and the decrease in gammaglobulin levels in patients with systemic lupus erythematosus ( 19)L Several case studies of scleromyxoedema indicate a benefit from single long-term thalidomide at a dosage of 150^00 mg/dayj (18)(19)(20)(21)(22) if patients undergo strictly controlled contraception as well as baseline and biannual nerve studitis (23).…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, thalidomide has been proposed to be an anti-fibrotic agent through its immuiioregulatory effect on pro-inflammatory and pro-fiblrotic cytokines in myelodysplastic syndrome with bone-marrow fibrosis and the decrease in gammaglobulin levels in patients with systemic lupus erythematosus ( 19)L Several case studies of scleromyxoedema indicate a benefit from single long-term thalidomide at a dosage of 150^00 mg/dayj (18)(19)(20)(21)(22) if patients undergo strictly controlled contraception as well as baseline and biannual nerve studitis (23). However, the development of neuropathy as a significant adverse event remains a major limitation tO:an acceptable risk-to-benefit ratio, as documented also in our patient.…”
Section: Discussionmentioning
confidence: 99%